Union Bancaire Privee UBP SA Lowers Stock Position in Becton, Dickinson and Company $BDX

Union Bancaire Privee UBP SA lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 24.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 230 shares of the medical instruments supplier’s stock after selling 75 shares during the quarter. Union Bancaire Privee UBP SA’s holdings in Becton, Dickinson and Company were worth $40,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Saudi Central Bank purchased a new position in Becton, Dickinson and Company during the first quarter worth about $26,000. Smallwood Wealth Investment Management LLC purchased a new position in Becton, Dickinson and Company during the first quarter worth about $27,000. Alpine Bank Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth about $29,000. Cornerstone Planning Group LLC lifted its position in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth about $31,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 2.0%

Shares of NYSE:BDX opened at $190.90 on Thursday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The stock has a market cap of $54.72 billion, a price-to-earnings ratio of 34.33, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25. The firm’s 50 day moving average price is $188.71 and its 200 day moving average price is $188.20. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the firm posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BDX. Royal Bank Of Canada began coverage on shares of Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 price target on the stock. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Piper Sandler reissued a “neutral” rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Argus raised their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and an average target price of $205.40.

Insider Buying and Selling

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,023 shares of company stock worth $562,036. Insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.